Picture this: It’s a Tuesday night. Mrs. Henderson, a longtime wet AMD patient, is sitting on her couch in pajamas, sipping chamomile tea. She picks up a small device that looks a bit like a pair of binoculars from a sci-fi film, rests her chin on it, and takes a 60-second OCT scan of her own macula. Somewhere in the cloud, an AI algorithm quietly flags a new pocket of intraretinal fluid. By the time her optometrist opens the inbox the next morning, there’s an alert waiting, along with a recommendation to bring her in for an earlier injection.
No waiting room, parking ticket or 40-mile drive from her daughter’s house in the next county over. Just a nudge from a machine that never sleeps.
Welcome to the home eye exam, 2026 edition.
From Snellen Charts to Smart Screens
For most of our professional lives, “home monitoring” meant handing a patient a paper Amsler grid, reminding them to tape it to the fridge, and hoping they would actually use it. We all know how that usually ended. The grid became a backdrop for grocery lists, and metamorphopsia went unreported until a patient lost three lines of acuity.
What has changed is not just the technology but the philosophy. AI has quietly turned the patient’s smartphone, tablet and now even countertop OCT into a node in a continuous monitoring network. The result is a shift from episodic care, where patients are seen every three to six months, to something much closer to continuous care. As one recent analysis in Eye put it, digital health innovations in ophthalmology now span self-monitoring home devices and apps, virtual and augmented reality aids, AI software and wearables, giving us ecologically valid data from the patient’s day-to-day life rather than a single snapshot under clinic lighting.
That is a big deal. And it is already reshaping how we counsel patients, structure follow-ups and think about reimbursement.
What’s Actually on the Market Right Now
Let’s get concrete, because patients certainly will. Here are the FDA-cleared tools optometrists are most likely to be asked about in 2026.
SCANLY Home OCT by Notal Vision
The headline act. In 2024, Notal Vision’s Home OCT received FDA authorization as the first patient-operated OCT for neovascular AMD. The device uses an 830 nm spectral-domain platform to capture 88 B-scans across a 3 mm by 3 mm area of the macula. Scans are uploaded to the Notal Health Cloud, where the Notal OCT Analyzer segments hyporeflective spaces and quantifies fluid volume. Keenan and colleagues showed the AI had strong agreement with human graders, and real-world deployment is now underway in retina practices across the country.
ForeseeHome (Notal Vision)
The older sibling, but still going strong. FDA cleared and Medicare covered, it uses preferential hyperacuity perimetry to flag conversion from intermediate to wet AMD. The HOME study famously showed that ForeseeHome users maintained better acuity at conversion (median 20/39) than those monitored by standard care alone. Medicare coverage makes the patient conversation a lot easier.
Alleye (Oculocare Medical)
A smartphone and tablet app that received FDA 510(k) clearance in 2018 for detecting and monitoring AMD. It screens for metamorphopsia using a dot-alignment task over the central 12 degrees. Schmid and colleagues found it detects wet AMD with solid accuracy. It is a good fit for tech-hesitant patients, because if they can tap a dot on a screen, they can use Alleye.
myVisionTrack (mVT)
The first FDA-cleared ophthalmic app, originally cleared in 2013 and acquired by Genentech in 2019. It uses shape discrimination hyperacuity to monitor patients with AMD, diabetic retinopathy and diabetic macular edema. Results flow to a physician portal, which also has its own FDA clearance, making mVT particularly useful for structured follow-up between clinic visits.
GoCheck Kids
The FDA-cleared smartphone photoscreener that has quietly made its way into thousands of pediatric offices. Studies have pegged sensitivity for amblyopia risk factors at 76 to 90%, depending on the cohort. For parents worried about their 3-year-old’s first eye check, it is a low-stakes entry point that often brings them into our chairs sooner.
What This Looks Like in Real Life
The devices are interesting on their own, but the real story is how they change the day-to-day experience of care. A few examples make it clearer.
Take wet AMD. Under the old model, we saw a patient every four to six weeks, made a treatment decision based on that one snapshot and sent them home until the next visit. If fluid built up in between, we only found out when the next scan caught it.
With daily home OCT, the picture is very different. We can see trends, not just snapshots. A patient whose retina stays dry for weeks can have injections safely spaced further apart. Another whose fluid creeps up between visits can be brought in early, before vision drops. The decision to treat or wait stops being a guess and starts being informed by hundreds of data points.
Diabetic retinopathy tells a similar story from a different angle. Roughly half of Americans with diabetes skip their yearly dilated eye exam. The reasons are familiar: the appointment is inconvenient, the drops are annoying and the clinic is far away. AI tools like AEYE-DS from AEYE Health and EyeArt from Eyenuk, both FDA cleared, let a family doctor snap a retinal photo during a routine diabetes visit and get an AI-generated screening result in under a minute. No dilation, no specialist referral for the low-risk patients, no long drive. The patients who need us most get flagged and sent our way. The rest go home reassured.
And for pediatrics, a 3-year-old who would never cooperate with a Snellen chart can be screened in 30 seconds with a GoCheck Kids photo. Parents leave the pediatrician’s office knowing whether their child needs to see us, rather than wondering about it for another year.
These are not future scenarios. They are happening in clinics across the country right now.
Eye Care as the Front Door to Systemic Health
Here is the bigger picture. Eye care is quietly becoming a starting point for whole-body health, not just vision.
Consider what makes our profession unique. The eye is the only place in the human body where a clinician can directly visualize live tissue, nerve fiber and microvasculature, noninvasively and without a scalpel, needle, or contrast agent. Every retinal scan is a window into systemic health. Hypertension, diabetes, multiple sclerosis, Alzheimer’s disease, sickle cell disease and cardiovascular risk all leave fingerprints on the retina, the optic nerve and the microvascular network behind the lens.
When AI is layered on top of that unique vantage point, and when home-based imaging feeds data into the system every single day, something remarkable happens. The optometrist’s chair becomes a hub for early detection across the body. A subtle change in retinal nerve fiber layer thickness, picked up by a home scan and flagged by an algorithm, can be the first hint of neurodegenerative disease. A shift in retinal microvasculature can precede a cardiovascular event. A pattern of fluid fluctuation can reflect how well a diabetic is truly managing their glucose.
That is the bigger opportunity. The optometrist’s chair becomes the place where systemic disease gets spotted first, not just vision changes. Our value is in putting the data in context, calibrating treatment, communicating with primary care and specialists and being the human that the algorithm refers back to.
There are still caveats worth airing. Reimbursement for home OCT review is uneven, and ForeseeHome adoption stalled partly because of that. Usability matters for older patients, many of whom have arthritis, cognitive changes, or low vision that make device operation tricky. And the volume of data is real. Nobody wants 365 OCT scans per patient per year landing in their inbox without smart triage.
But the direction is set. The home eye exam is no longer a novelty. It is becoming infrastructure, and eye care is sitting at the intersection of vision, systemic health and AI-driven continuous monitoring. That is a profession stepping into a bigger role than it has ever held before.
References
1 Keenan TDL, et al. Home OCT in neovascular AMD: Agreement between the Notal OCT Analyzer and human graders. Ophthalmology Retina. 2022.
2 Schmid MK, et al. Reliability and diagnostic performance of a novel mobile app for hyperacuity self-monitoring in patients with age-related macular degeneration. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2019.
3 Chew EY, et al. Randomized trial of the ForeseeHome monitoring device for early detection of neovascular AMD: The HOME Study. Ophthalmology. 2014;121(2):535-544.
4 Notal Vision. SCANLY Home OCT product information. https://notalvision.com/services/scanly-oct
5 U.S. Food and Drug Administration. 510(k) Clearance K173677 (Alleye, Oculocare Medical Inc.), 2018.
6 U.S. Food and Drug Administration. 510(k) Clearance for myVisionTrack (Vital Art and Science), 2013.
7 AEYE Health. AEYE-DS autonomous AI for diabetic retinopathy screening; Epic integration announcement, January 2026.
8 Eyenuk. EyeArt AI Eye Screening System clinical validation summary. https://www.eyenuk.com
9 Miller JB, et al. Digital health and wearable devices for retinal disease monitoring. Eye (London). 2024.
10 American Academy of Ophthalmology. Monitoring AMD With Home-Based OCT. EyeNet Magazine. 2023.
11 Bascom Palmer Eye Institute. Digital EyeCon 2026: Tomorrow’s Care, Today: AI & RPM in Focus. April 17-18, 2026.
Read more from AI in Eye Care here
Author
